FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005406336> ?p ?o ?g. }

• W3005406336 endingPage "101902" @default.
• W3005406336 startingPage "101902" @default.
• W3005406336 abstract "Indacaterol is one of the long-acting beta2-adrenergic agonists, referred as first-line monotherapy for Chronic obstructive pulmonary disease since 2011. Generic products are encouraged to benefit the large COPD patients in China, in which can provide more choices association with reduced cost and improve the quality of patient life. The three-part study consists of two independent cohorts of thirty-six subjects, aimed to evaluate the bioequivalence (BE) of two indacaterol formulations in gastrointestinal (GI) absorption charcoal-block or non-block conditions. One pilot study performed in six healthy subjects to determine the blocking effect of a new charcoal-based regimen on GI absorption after orally inhalation of indacaterol. Two BE studies were conducted with a randomized, open-label, 2-period crossover design in two independent 36-healthy-subject cohorts, equivalence in systemic and lung deposition was assessed after inhalation of a single dose of 150 μg indacaterol (test or reference formulation) alone or concomitant administration of charcoal. The charcoal-based regimen was improved by optimizing the dose and number of doses, and its blocking efficacy against GI absorption was assessed in a pilot study. Six healthy subjects received 9 g charcoal 10 min before, immediately after and 2 h after indacaterol (3 g/100 ml water × 3 times). Blood collected at predetermined time points up to 72 h. Plasma indacaterol concentrations were determined using HPLC-MS/MS. Pharmacokinetics parameters were calculated with non-compartment analysis. Equivalences were concluded if the 90% confidence interval (CI) for test: reference of Cmax and AUC0-t fell within the limits of 0.8–1.25. Indacaterol was undetectable in plasma samples in pilot study. The T/R ratio of the geometric mean Cmax and AUC0-t was 109.9% (90% CI, 106.1–113.8%) and 104.8% (90% CI, 101.5–108.1%) for charcoal-block subjects and 105.4% (90% CI, 99.8% ~ 111.3%), and 101.0% (90% CI, 97.7%–104.4%) for non-block subjects. No serious adverse events were reported. The results showed that 150 μg indacaterol (+/− 9 g charcoal) was well tolerated in all subjects. The two formulations are bioequivalent in terms of the rate and absorption both in charcoal-block and non-block conditions. The improved charcoal-based regimen demonstrated to be effective and fully blockade of GI absorption of indacaterol." @default.
• W3005406336 created "2020-02-14" @default.
• W3005406336 creator A5003974512 @default.
• W3005406336 creator A5008396784 @default.
• W3005406336 creator A5013228003 @default.
• W3005406336 creator A5028600976 @default.
• W3005406336 creator A5030939361 @default.
• W3005406336 creator A5040306516 @default.
• W3005406336 creator A5050748359 @default.
• W3005406336 creator A5065610505 @default.
• W3005406336 creator A5085521489 @default.
• W3005406336 date "2020-04-01" @default.
• W3005406336 modified "2023-09-27" @default.
• W3005406336 title "Bioequivalence studies of inhaled indacaterol maleate in healthy Chinese volunteers under gastrointestinal non-blocking or blocking with concomitant charcoal administration" @default.
• W3005406336 cites W1544938778 @default.
• W3005406336 cites W1796604713 @default.
• W3005406336 cites W1892949664 @default.
• W3005406336 cites W1966475738 @default.
• W3005406336 cites W1985584819 @default.
• W3005406336 cites W2005940446 @default.
• W3005406336 cites W2010566912 @default.
• W3005406336 cites W2010810014 @default.
• W3005406336 cites W2014664741 @default.
• W3005406336 cites W2014822095 @default.
• W3005406336 cites W2026301883 @default.
• W3005406336 cites W2042513423 @default.
• W3005406336 cites W2045616259 @default.
• W3005406336 cites W2053575565 @default.
• W3005406336 cites W2057359869 @default.
• W3005406336 cites W2061675554 @default.
• W3005406336 cites W2067454015 @default.
• W3005406336 cites W2080185259 @default.
• W3005406336 cites W2098680476 @default.
• W3005406336 cites W2098695479 @default.
• W3005406336 cites W2124596793 @default.
• W3005406336 cites W2219840098 @default.
• W3005406336 cites W2268114278 @default.
• W3005406336 doi "https://doi.org/10.1016/j.pupt.2020.101902" @default.
• W3005406336 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32045673" @default.
• W3005406336 hasPublicationYear "2020" @default.
• W3005406336 type Work @default.
• W3005406336 sameAs 3005406336 @default.
• W3005406336 citedByCount "2" @default.
• W3005406336 countsByYear W30054063362022 @default.
• W3005406336 crossrefType "journal-article" @default.
• W3005406336 hasAuthorship W3005406336A5003974512 @default.
• W3005406336 hasAuthorship W3005406336A5008396784 @default.
• W3005406336 hasAuthorship W3005406336A5013228003 @default.
• W3005406336 hasAuthorship W3005406336A5028600976 @default.
• W3005406336 hasAuthorship W3005406336A5030939361 @default.
• W3005406336 hasAuthorship W3005406336A5040306516 @default.
• W3005406336 hasAuthorship W3005406336A5050748359 @default.
• W3005406336 hasAuthorship W3005406336A5065610505 @default.
• W3005406336 hasAuthorship W3005406336A5085521489 @default.
• W3005406336 hasConcept C112705442 @default.
• W3005406336 hasConcept C126322002 @default.
• W3005406336 hasConcept C142724271 @default.
• W3005406336 hasConcept C204787440 @default.
• W3005406336 hasConcept C22979827 @default.
• W3005406336 hasConcept C27081682 @default.
• W3005406336 hasConcept C2776042228 @default.
• W3005406336 hasConcept C2776954882 @default.
• W3005406336 hasConcept C2778884479 @default.
• W3005406336 hasConcept C2779384505 @default.
• W3005406336 hasConcept C2781018748 @default.
• W3005406336 hasConcept C2781413609 @default.
• W3005406336 hasConcept C42219234 @default.
• W3005406336 hasConcept C42404028 @default.
• W3005406336 hasConcept C44249647 @default.
• W3005406336 hasConcept C71924100 @default.
• W3005406336 hasConcept C87813604 @default.
• W3005406336 hasConcept C98274493 @default.
• W3005406336 hasConceptScore W3005406336C112705442 @default.
• W3005406336 hasConceptScore W3005406336C126322002 @default.
• W3005406336 hasConceptScore W3005406336C142724271 @default.
• W3005406336 hasConceptScore W3005406336C204787440 @default.
• W3005406336 hasConceptScore W3005406336C22979827 @default.
• W3005406336 hasConceptScore W3005406336C27081682 @default.
• W3005406336 hasConceptScore W3005406336C2776042228 @default.
• W3005406336 hasConceptScore W3005406336C2776954882 @default.
• W3005406336 hasConceptScore W3005406336C2778884479 @default.
• W3005406336 hasConceptScore W3005406336C2779384505 @default.
• W3005406336 hasConceptScore W3005406336C2781018748 @default.
• W3005406336 hasConceptScore W3005406336C2781413609 @default.
• W3005406336 hasConceptScore W3005406336C42219234 @default.
• W3005406336 hasConceptScore W3005406336C42404028 @default.
• W3005406336 hasConceptScore W3005406336C44249647 @default.
• W3005406336 hasConceptScore W3005406336C71924100 @default.
• W3005406336 hasConceptScore W3005406336C87813604 @default.
• W3005406336 hasConceptScore W3005406336C98274493 @default.
• W3005406336 hasLocation W30054063361 @default.
• W3005406336 hasOpenAccess W3005406336 @default.
• W3005406336 hasPrimaryLocation W30054063361 @default.
• W3005406336 hasRelatedWork W2008610508 @default.
• W3005406336 hasRelatedWork W2104641112 @default.
• W3005406336 hasRelatedWork W2131666897 @default.
• W3005406336 hasRelatedWork W2253621234 @default.
• W3005406336 hasRelatedWork W2359939078 @default.

• next